Atossa Therapeutics Engages Investors at Maxim Growth Summit for Breast Cancer Innovations

Atossa Therapeutics Engages Investors at Maxim Growth Summit

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, actively seeks new investors by participating in the upcoming Maxim Growth Summit scheduled for October 22–23, 2025, in New York City. The event serves as a critical platform for Atossa's leadership, particularly its Chairman and CEO, Dr. Steven Quay, who will deliver a presentation and engage in one-on-one meetings with prospective investors. This initiative underscores Atossa's commitment to transparent communication and strategic partnership opportunities as it advances its innovative therapies aimed at addressing the unmet needs in breast cancer treatment.

The company articulates a clear focus on disciplined capital allocation, channeling resources toward programs with the potential for regulatory submissions and eventual commercialization. Atossa emphasizes that this strategic approach not only addresses significant gaps in breast cancer care but also positions the company for long-term value creation. By concentrating on the development of therapies that can enhance patient outcomes, Atossa aims to establish itself as a leader in the biopharmaceutical industry, particularly in the oncology sector.

Atossa's participation in the summit reflects its dedication to engaging with investors and stakeholders, providing them with insights into development plans, milestones, and expected returns on research and development investments. Additionally, the company encourages interested parties to explore its latest presentations and SEC filings available on its website, further reinforcing its commitment to transparency and accessibility. By offering direct access to its leadership team, Atossa fosters an environment where investors can delve into the company’s strategic vision and innovations in breast cancer treatment.

In conjunction with the summit activities, Atossa highlights the importance of its forward-looking statements regarding program updates, study costs, and anticipated timelines. These statements serve to inform investors of the inherent risks and uncertainties that may impact actual outcomes, ensuring that potential stakeholders are fully aware of the landscape surrounding the company's initiatives.

To facilitate engagement, Atossa invites interested investors to request one-on-one meetings or to access its latest investor deck through its website. By prioritizing communication and transparency, Atossa Therapeutics continues to position itself as a vital player in the quest to improve breast cancer care and treatment outcomes.